Efforts to develop P2X7 drugs are hampered by species differences. Here, authors reveal the structural basis for these disparities and show that transgenic mice provide a powerful model for testing selective inhibitors with greater clinical relevance.
- Chang-Run Guo
- Danqi Sheng
- Ye Yu